Samsung Biologics has received a Platinum rating from sustainability assessor EcoVadis, placing the South Korean biopharmaceutical manufacturer among the top 1% of companies globally for environmental, social and governance performance.
EcoVadis said Jan. 29 that it awarded Samsung Biologics the highest possible grade in its 2026 ESG assessment. The Paris-based firm evaluates more than 150,000 companies across 175 countries each year.
Companies are assessed across four categories—environment, labor and human rights, ethics, and sustainable procurement—with only the top 1% qualifying for Platinum status.
The designation is expected to bolster Samsung Biologics’ appeal to global pharmaceutical clients, as large drugmakers increasingly require EcoVadis scores as part of supplier qualification and supply-chain risk management.
EcoVadis cited improvements in the company’s ESG governance, including strengthened policy frameworks and enhanced sustainability disclosures. The assessment also highlighted Samsung Biologics’ participation in global initiatives such as the Sustainable Markets Initiative and the United Nations Global Compact.
In labor and human rights, the company earned high marks for diversity and equity policies, anti-discrimination training and structured labor-management communication. On the environmental front, EcoVadis pointed to Samsung Biologics’ commitment to achieving net-zero carbon emissions by 2050 and its participation in the RE100 renewable-energy program.
Major pharmaceutical companies including GSK and AstraZeneca use EcoVadis ratings as a key benchmark when evaluating suppliers, underscoring the commercial relevance of the Platinum award.
“Through comprehensive efforts ranging from climate-change 대응 to systematic supply-chain management, we have demonstrated our ESG competitiveness in the global market,” said John Rim, chief executive of Samsung Biologics. “We will continue to strengthen sustainable management practices as a leading global CDMO.”
